Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients

被引：20

作者：

Takimoto, Takayuki ^{[1
]}

Nakabori, Tasuku ^{[1
]}

Osa, Akio ^{[1
]}

Morita, Satomu ^{[1
]}

Terada, Haruko ^{[1
]}

Oseto, Susumu ^{[1
]}

Iwazawa, Takashi ^{[2
]}

Abe, Kinya ^{[1
]}

机构：

[1] Toyonaka City Hosp, Dept Internal Med, Toyonaka, Osaka 5608565, Japan

[2] Toyonaka City Hosp, Dept Surg, Toyonaka, Osaka 5608565, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 17卷 / 04期

关键词：

Non-small-cell lung cancer (NSCLC); Chronic renal failure; Docetaxel; Tubular nephrotoxicity; beta(2)-Microglobulin; RENAL-FUNCTION; CISPLATIN; CHEMOTHERAPY; PLATINUM; TAXOTERE;

D O I：

10.1007/s10147-011-0304-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.

引用

页码：395 / 398

页数：4

共 50 条

[1] Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients
Takayuki Takimoto
Tasuku Nakabori
Akio Osa
Satomu Morita
Haruko Terada
Susumu Oseto
Takashi Iwazawa
Kinya Abe
International Journal of Clinical Oncology, 2012, 17 : 395 - 398
[2] Integration of docetaxel in the management of non-small-cell lung cancer
Belani, CP
LUNG CANCER, 2004, 46 : S1 - S2
[3] Development of docetaxel in advanced non-small-cell lung cancer
Belani, CP
Eckardt, J
LUNG CANCER, 2004, 46 : S3 - S11
[4] Docetaxel in the treatment of advanced non-small-cell lung cancer
Saloustros, Emmanouel
Georgoulias, Vassilis
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1207 - 1222
[5] Docetaxel for previously treated non-small-cell lung cancer
Fossella, FV
ONCOLOGY-NEW YORK, 2002, 16 (06): : 45 - 51
[6] Docetaxel plus cisplatin in non-small-cell lung cancer
Chandra Belani
Sakkaraiappan Ramalingam
Vassilis Georgoulias
George Simon
Drugs & Therapy Perspectives, 2004, 20 (3) : 7 - 9
[7] Gefitinib or docetaxel in advanced non-small-cell lung cancer
Cullen, Michael
Thatcher, Nicholas
LANCET, 2008, 372 (9652): : 1785 - 1786
[8] Weekly chemotherapy of cisplatin and docetaxel for elderly patients with non-small-cell lung cancer
Ohe, Y
Niho, S
Minami, H
Saijo, N
Watanabe, K
Yokoyama, A
Nishiwaki, Y
LUNG CANCER, 2004, 45 : S76 - S77
[9] Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
Karampeazis, Athanasios
Georgoulias, Vassilis
CLINICAL LUNG CANCER, 2012, 13 (05) : 397 - 397
[10] Docetaxel as monotherapy in the treatment of advanced non-small-cell lung cancer in elderly patients
Malani, Ashok K.
Abou-Jawde, Rony M.
Singh, Jaswinder
Taylor, Sarah A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1143 - 1144

← 1 2 3 4 5 →